cis-2-(methylamino)cyclohexanecarboxamide | 54867-14-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cis-2-(methylamino)cyclohexanecarboxamide
• 英文别名: (1S,2R)-2-(methylamino)cyclohexane-1-carboxamide
• CAS: 54867-14-0
• 化学式: C₈H₁₆N₂O
• 分子量: 156.228
• InChiKey: HYXNUCJQDGCKCW-NKWVEPMBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  cis-2-(methylamino)cyclohexanecarboxylic acid 在 palladium on activated charcoal sodium hydroxide 、 氨 、 氢气 、 三乙胺 、 氯甲酸异丁酯 作用下， 以 乙醇 为溶剂， -10.0~25.0 ℃ 、101.33 kPa 条件下， 反应 21.25h， 生成 cis-2-(methylamino)cyclohexanecarboxamide
  参考文献：
  名称：

  Goendoes, Gyoergy; Szecsenyi, Istvan; Dombi, Gyoergy, Liebigs Annalen der Chemie, 1991, # 6, p. 591 - 593

  摘要：

  DOI：

文献信息

• BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY
  申请人：BYLOCK Lars Anders

  公开号：US20130236468A1

  公开（公告）日：2013-09-12

  The present invention relates to a combination comprising compounds of formula (I): wherein R 1 to R 3 , A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.

  本发明涉及一种组合物，包括式（I）的化合物： 其中R1至R3，A，X和n如本文所定义，并且另外包括一种活性剂。本发明还涉及包括这些组合物的药物组合物，以及使用这些组合物治疗各种疾病和疾病的方法。
• PYRIMIDINE COMPOUND
  申请人：Matsushima Yuji

  公开号：US20110053912A1

  公开（公告）日：2011-03-03

  A novel and excellent method for preventing and/or treating diseases related to a cannabinoid type 2 receptor, based on an agonistic action on a cannabinoid type 2 receptor. It was found that a hetero ring derivative mainly having two substituents, for example, a pyrimidine-5-carboxamide derivative having a substituent amino group at the 2-position, exhibits a potent agonistic action on a cannabinoid type 2 receptor, and can be an agent for preventing and/or treating diseases related to a cannabinoid type 2 receptor such as inflammatory diseases, pain, and the like.

  一种预防和/或治疗与大麻素2型受体相关疾病的新颖优秀方法，基于对大麻素2型受体的激动作用。发现一种异核环衍生物主要具有两个取代基，例如，在2-位置具有取代基氨基的嘧啶-5-羧酰胺衍生物，表现出对大麻素2型受体的强效激动作用，可以成为预防和/或治疗与大麻素2型受体相关疾病，如炎症性疾病、疼痛等的药物。
• Bicyclic pyrimidine derivatives
  申请人：Arai Hitoshi

  公开号：US20070037834A1

  公开（公告）日：2007-02-15

  [wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m+n is 4 or less; R 1 represents —NR 4 R 5 (wherein R 4 and R 5 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); R 2 represents the above Formula (II), Formula (IV) or the like; A represents a single bond, —C(═O)—, —SO 2 —, —OC(═O)— or the like; and R 3 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like] Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related to T cells, such as an allergic disease, an autoimmune disease or transplant rejection.

  提供上述公式（I）所代表的双环嘧啶衍生物，其中m和n可以相同或不同，每个表示1至3的整数，其中m+n小于等于4；R1表示—NR4R5（其中R4和R5可以相同或不同，每个表示氢原子，取代或未取代的低碳基，取代或未取代的芳基烷基或类似物）；R2表示上述公式（II），公式（IV）或类似物；A表示单键，—C（═O）—，—SO2—，—OC（═O）—或类似物；R3表示取代或未取代的低碳基，取代或未取代的环烷基，取代或未取代的芳基烷基或类似物。还提供了上述公式（I）所代表的四元铵盐或药学上可接受的盐或类似物。这些化合物具有抗炎活性或对TARC和/或MDC功能的调节活性，并且用于治疗和/或预防与T细胞相关的疾病，例如过敏性疾病，自身免疫性疾病或移植排斥。
• BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION
  申请人：Abeywardane Asitha

  公开号：US20130196973A1

  公开（公告）日：2013-08-01

  The present invention relates to compounds of formula (I): wherein R 1 to R 3 , A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A 4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式(I)化合物，其中R1至R3，A，X和n的定义如本文所述。式(I)化合物可用作白三烯A4水解酶（LTA4H）的抑制剂，并用于治疗LTA4H相关疾病。本发明还涉及包含式(I)化合物的制药组合物，使用这些化合物治疗各种疾病和疾患的方法，以及制备这些化合物的方法。
• [EN] THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS THIÉNYL ET CYCLOALKYL AMINOPYRIMIDINES UTILISÉS COMME INHIBITEURS DE KINASES NUAK, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2022147620A1

  公开（公告）日：2022-07-14

  The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting or blocking NUAK kinase, such as cancers and fibrosis.

  本申请涉及式（I）化合物或其药学上可接受的盐、溶剂或前药，以及包含这些化合物或其药学上可接受的盐、溶剂或前药的组合物，以及在治疗可通过抑制或阻断NUAK激酶来治疗的疾病、紊乱或病况方面的各种用途，例如癌症和纤维化。